Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Lilly turned in strong first-quarter results, powered by its GLP-1 weight-loss drugs. But news about its Zepbound drug, along with lowered profit guidance, hurt the shares. The company's new oral ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... tirzepatide achieved at least 25% body weight loss compared to 16.1% of those receiving ...

Drugmaker Eli Lilly announced promising Phase 3 study results ... diabetes and weight loss. The drug is in the same class of GLP-1 medications as Ozempic, Wegovy, Mounjaro, and Zepbound ...

Medications targeting weight loss like Wegovy and Zepbound are part of a relatively ... as not only life-changing but also lifesaving. The results have led to a surge in popularity in recent ...

Currently, only liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound ... your potential results, it can increase the likelihood of maintaining weight loss in the long term.

CVS Health will drop the weight-loss drug Zepbound from its insured pharmacy options this summer. Employers and insurers may ...